PR87141

SOMERSET, N.J., Dec. 11, 2020 /PRNewswire=KYODO JBN/ --

Catalent, the leading global provider of advanced delivery technologies,

development, manufacturing and clinical supply solutions for drugs, biologics,

cell and gene therapies, and consumer health products, today announced the

appointment of Nakaya "Nick" Matsumaru as General Manager of its new clinical

packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Photo: https://mma.prnewswire.com/media/1373058/GM_Pic.jpg

Caption: Nakaya Matsumaru, GM of Shiga facility

Reporting to Roel de Nobel, Catalent's Vice President of Operations for Europe

and Asia-Pacific, Mr. Matsumaru joins the company from SymBio Pharmaceuticals

Ltd, where he held the role of Senior Director Supply Chain & Quality

Assurance. Prior to this, he spent four years in vice president, executive

officer and head of operations posts with AstraZeneca, and seven years in

Japan-based supply chain management with Johnson & Johnson and Janssen. He

holds a bachelor's degree in sociology from Keio University in Tokyo.

"We are pleased to welcome Nick to head our clinical supplies business at our

new facility in Shiga, which in partnership with our existing Japanese facility

in Kakegawa, will provide flexible clinical supply solutions to customers in

Japan and global biotech and pharmaceutical companies," commented Mr. de Nobel.

He added, "Nick brings a great deal of experience, and will play an important

role in the ongoing expansion of Catalent's Asia-Pacific network and ensuring

that customers' clinical trials continue to be well-served across the region, and worldwide."

Catalent announced it had completed the acquisition of the 60,000-square-foot

facility in Shiga from Teva-Takeda Pharmaceuticals in July 2020. The facility

is the latest in Catalent's expanding Asia-Pacific clinical supplies network,

and alongside the existing Japanese facility in Kakegawa, the  company's two

sites in China and one in Singapore it will offer extensive services including

access to primary and secondary packaging capabilities, Catalent's FastChain(R)

demand-led supply services, a range of temperature options for storage and

distribution, as well as clinical returns and destruction services.

About Catalent Clinical Supply Services

Catalent is a global leader in clinical supply services, with comprehensive and

flexible solutions for small molecules, biologics, and cell and gene therapies

and integrated solutions to accelerate speed to clinic. Catalent offers a full

range services including clinical supply management, comprehensive packaging

solutions, comparator sourcing, cold chain storage and global distribution and

specialized supply chain services including direct-to-patient and demand-led

supply. With nine GMP clinical packaging facilities and over 50 strategically

located depots on six continents combined with more than 25 years' experience

across thousands of studies in more than 80 countries, Catalent has the

comprehensive services, global scale and expertise necessary to reliably supply

clinical trials of all sizes and complexity anywhere in the world.

About Catalent

Catalent (NYSE:CTLT) is the leading global provider of advanced delivery

technologies, development, and manufacturing solutions for drugs, biologics,

cell and gene therapies, and consumer health products. With over 85 years

serving the industry, Catalent has proven expertise in bringing more customer

products to market faster, enhancing product performance and ensuring reliable

global clinical and commercial product supply. Catalent employs approximately

14,000 people, including around 2,400 scientists and technicians, at more than

45 facilities, and in fiscal year 2020 generated over $3 billion in annual

revenue. Catalent is headquartered in Somerset, New Jersey. For more

information, visit www.catalent.com

More products. Better treatments. Reliably supplied.(TM)

Source: Catalent